Ruxolitinib plus decitabine in post-MPN AML
Second-line myelofibrosis treatment – the potential of JAK2 inhibitor NS-018
Myeloma 2016: Panel discussion on gene modified T-cells
Edward Stadtmauer et al.
Cytokine release syndrome: a limiting factor for AML treatment
Update on immunotherapy trials for AML from ASH 2017: bispecific DARTs, CAR T-cells and ADCs